Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-06-07
Based on 1205 first isolates · PHC-N · Cystitis (lower UTI) · 2025-06-08 → 2026-06-07
Health centre North
Per-organism detail: PHC-N urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (80 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
83 %
82 %
n = 143
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
85 %
n = 143
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
79 %
n = 143
ciprofloxacin CIP
trend · Escherichia coli
77 %
77 %
n = 143
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
76 %
n = 143
ceftriaxone CRO
trend · Escherichia coli
75 %
76 %
n = 143
72 %
71 %
n = 143
trimethoprim TMP
trend · Escherichia coli lower UTI only
71 %
66 %
n = 143
52 %
53 %
n = 143
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
16 %
n = 143
5 %
5 %
n = 143
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 143

Most likely organisms for this profile

Escherichia coli
51 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
11 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.